Fenwick & West represented Myonexus Therapeutics, a clinical-stage biotechnology company developing transformative gene therapies for various forms of limb-girdle muscular dystrophies (LGMDs), with respect to the intellectual property and licensing aspects of its transaction with Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Under this transaction, Sarepta will make an upfront payment of $60 million and additional development-related milestone payments to purchase an exclusive option to acquire Myonexus at a pre-negotiated, fixed price with sales-related contingent payments. More information about this transaction can be obtained from Myonexus Therapeutics’ press release.
Stefano Quintini assisted Myonexus with support from technology transaction partner Jake Handy.